FDA Adds Boxed Warning to Canagliflozin for Amputation Risk FDA Adds Boxed Warning to Canagliflozin for Amputation Risk
On the basis of new information from two cardiovascular outcomes trials suggesting a doubled amputation risk, the FDA will now require a boxed warning on canagliflozin ' s label.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: Canagliflozin | Cardiology | Cardiovascular | Diabetes | Endocrinology | Health | Heart | Invokana | Warnings